RxDoctor Payments Data

Cassey Cuevas

Psychiatric/Mental Health · St Augustine, FLNPI 1659061646

Payments from drug & device makers

$1,678in general payments, 2019–2025

Across 64 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$401
  • Johnson & Johnson$393
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$307
  • Teva Pharmaceuticals USA, Inc.$193
  • Otsuka America Pharmaceutical, Inc.$102
  • Alkermes, Inc.$82
  • plus $201 from 5 others

What the payments were for

  • Food & beverage$1,678100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678 in reported general payments places this provider in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$1,124
Medicare patients
13
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate17$143,429
Abilify MaintenaAripiprazole19$51,654
VraylarCariprazine Hcl32$43,148
Invega SustennaPaliperidone Palmitate12$39,121
TrintellixVortioxetine Hydrobromide49$24,696
Lurasidone Hcl37$5,952
Hydroxyzine Pamoate65$1,358
Haloperidol Decanoate18$1,244
Divalproex Sodium ErDivalproex Sodium15$1,127
Chlorpromazine Hcl11$1,001
Duloxetine Hcl35$646
Buspirone Hcl23$614
Olanzapine37$612
Mirtazapine71$587
Quetiapine Fumarate64$453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$79$143,42917 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$102$51,65419 claims
AbbVieVraylar$401$43,14832 claims
Johnson & JohnsonInvega Sustenna$393$39,12112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$24,69649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →